Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited Operating Income Margin for the year ending March 31, 2024: 35.78%

Marksans Pharma Limited Operating Income Margin is 35.78% for the year ending March 31, 2024, a 130.34% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Marksans Pharma Limited Operating Income Margin for the year ending March 31, 2023 was 15.54%, a 7.40% change year over year.
Marksans Pharma Limited Operating Income Margin for the year ending March 31, 2022 was 14.47%, a -35.99% change year over year.
Marksans Pharma Limited Operating Income Margin for the year ending March 31, 2021 was 22.60%, a 49.91% change year over year.
Marksans Pharma Limited Operating Income Margin for the year ending March 31, 2020 was 15.07%, a 36.13% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Health Care
Industries Pharmaceuticals

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years